Michael Elliott Net Worth

Michael Elliott biography

Michael Elliott serves as Chief Scientific Officer of the Company. From December 2012 to August 2019, he served as Vice President, Immunology Scientific Innovation at Johnson & Johnson Innovation in Cambridge, Massachusetts, with responsibility for external collaborations and partnerships in immunology. Prior to 2012, Dr. Elliott held various senior positions at Johnson & Johnson, including General Manager and Site Head, TransForm Pharmaceuticals, Inc. (a division of Johnson & Johnson) and Senior Vice President, Immunology at Centocor, Inc. (a division of Johnson & Johnson), where he led the clinical development group. He currently serves on the board of Rhode Island Bio, a nonprofit life sciences industry organization and is a member of the Rhode Island Science and Technology Advisory Committee.

How old is Michael Elliott?

Michael Elliott is 61, he's been the Chief Scientific Officer of Immunovant Inc since 2020. There are 3 older and 12 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.

What's Michael Elliott's mailing address?

Michael's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.

Insiders trading at Immunovant Inc

Over the last 5 years, insiders at Immunovant Inc have traded over 21,959,710$ worth of Immunovant Inc stock and bought 3,433,213 units worth 88,718,319$ . The most active insiders traders include Sciences Ltd. Roivant、Peter Salzmann、Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of 1,150,148$. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth 104,979$.

What does Immunovant Inc do?

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.

Immunovant Inc executives and stock owners

Immunovant Inc executives and other stock owners filed with the SEC include:

• Peter Salzmann,
  Chief Executive Officer, Director
• Pamela Connealy,
  Chief Financial Officer
• Dr. Peter Salzmann M.B.A., M.D.,
  CEO & Director
• Frank Torti,
  Chairman of the Board
• Dr. Julia G. Butchko Ph.D.,
  Chief Devel. & Technology Officer
• Andrew Fromkin,
  Independent Director
• Douglas Hughes,
  Independent Director
• Atul Pande,
  Independent Director
• Dr. Frank M. Torti M.B.A., M.D., MBA,
  Exec. Chairperson of the Board
• George Migausky,
  Independent Director
• Eric Venker,
  Director
• W. Bradford Middlekauff,
  General Counsel
• Michael Elliott,
  Chief Scientific Officer
• Julia Butchko,
  Chief Development and Technology Officer
• Dr. William L. Macias M.D., Ph.D.,
  Chief Medical Officer
• Lauren Schrier M.B.A.,
  VP of Marketing
• Mark S. Levine,
  Chief Legal Officer & Corp. Sec.
• Tom Dorney M.B.A., M.S.,
  Director of Investor Relations & Strategy
• Eva Renee Barnett M.B.A.,
  Chief Financial Officer
• Sciences Holdings, Llc Health,
  10% owner
• Robert K Zeldin,
  Chief Medical Officer
• Myrtle S Potter,
  Director
• Jay S Stout,
  Chief Technology Officer
• Rita Jain,
  Chief Medical Officer
• William L. Macias,
  Chief Medical Officer
• Eva Renee Barnett,
  Chief Financial Officer
• Mark S. Levine,
  Chief Legal Officer
• Sciences Ltd. Roivant,
  
• Michael Geffner,
  Chief Medical Officer